Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod ...
Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announced today that it will be presenting a poster ...
Effective anti-tumor immunity is not only defined by which immune cells are present in a tumor, but also by how they are organized in space. Across cancer ...
A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals that launch immune responses with resolution measured in seconds. By combining ...
Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study. ・Anktiva was also ...
New research suggests the skin does much more than detect damage or keep pathogens out. By tracing how skin cells respond to ...
Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...